immunohistochemistry: 10-20 μg/mL using biotin / ExtrAvidin®-Peroxidase staining of heat-retrieved formalin-fixed, paraffin-embedded human skin sections western blot: 2.5-5.0 μg/mL using whole extract of HEK-293T cells overexpressing human CYLD
CYLD is a tumor suppressor protein exhibiting deubiquitination enzyme (DUB) activity, that specifically cleaves Lys63 -linked polyUb. CYLD contains a ubiquitin C-terminal hydrolase (UCH) domain, which is responsible for the removal of ubiquitin chains, and three cytoskeleton-associated protein-glycine conserved (CAP-Gly) domains, which are found in various microtubule-binding proteins.
应用
Anti-CYLD (C-terminal) antibody produced in rabbit has been used immunoblotting and immunohistochemistry.
生化/生理作用
CYLD physically interacts with many different proteins, some of which positively mediate signaling through the NF-κB and c-Jun N-terminal kinase (JNK) pathways and induces their deubiquitination. It controls cell proliferation, cell survival and inflammatory responses by negatively regulating NF-κB and/or JNK-signaling pathways. CYLD also regulates other physiological pathways such as cell cycle progression, spermatogenesis, and osteoclastogenesis. Mutations in the CYLD gene have been associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.
外形
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
法律信息
ExtrAvidin is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Mutations in the CYLD gene in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation
Bowen S, et al.
The Journal of Investigative Dermatology, 124(5), 919-920 (2005)
The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination
Kovalenko A, et al.
Nature, 424(6950), 801-801 (2003)
Premature aging and cancer development in transgenic mice lacking functional CYLD
Familial cylindromatosis is an autosomal dominant genetic predisposition to multiple tumours of the skin appendages. The susceptibility gene (CYLD) has previously been localized to chromosome 16q and has the genetic attributes of a tumour-suppressor gene (recessive oncogene). Here we have
The Journal of investigative dermatology, 133(7), 1870-1878 (2013-02-22)
CYLD is a tumor-suppressor gene mutated in the skin appendage tumors cylindromas, trichoepitheliomas, and spiradenomas. We have performed in vivo metastasis assays in nude mice and found that the loss of the deubiquitinase function of CYLD in squamous cell carcinoma